)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Proteomics International Laboratories (PIQ) investor relations material
Proteomics International Laboratories Bell Potter Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Bell Potter Healthcare Conference 2025 summary20 Nov, 2025
Product portfolio and market positioning
Four first-in-class diagnostic tests target diabetic kidney disease, esophageal cancer, endometriosis, and oxidative stress, all validated in large clinical studies and addressing significant unmet needs.
Tests are developed on immunoassay and mass spectrometry platforms, patented, and offer high margins, with a customer-driven strategy focused on primary care and GP clinics.
Digital platform built to support direct patient and physician engagement, attracting global key opinion leaders and strategic partners.
Commercial platform and infrastructure established in the U.S. and Australia, with labs and blood collection networks operational.
Funding, team, and certifications are in place to support ongoing launches and expansion.
Market launch, sales, and reimbursement
PromarkerD for diabetic kidney disease is live in Australia and California, with reimbursement pricing pending and expected to be set at $390 per test.
Early U.S. sales are self-pay, with insurance reimbursement to follow once pricing is finalized; Medicare coverage will be pursued nationwide after local determination.
Esophageal cancer and endometriosis tests are launching in Australia, with U.S. launches to follow; both address markets lacking non-invasive diagnostics.
Strategic focus is on building awareness, growing test volumes, and securing licensing and partnership deals through 2026.
No plans to expand headcount in 2026; commercial and digital teams are in place to support growth and partner engagement.
Market opportunity and clinical impact
U.S. diabetic kidney disease market includes 32 million diabetics and 30 million prediabetics, with PromarkerD able to predict risk up to four years in advance.
Early detection enables use of renal-protective drugs, improving patient outcomes and reducing healthcare costs.
Endometriosis test offers a non-invasive alternative to surgery, addressing a major gap in current care and attracting global interest.
Esophageal cancer test provides a less invasive option than endoscopy, recently launched in Australia with U.S. launch pending.
OxiDx test targets muscle damage and performance, with applications in sports medicine and animal welfare.
How will ProMarkerD US market expand post-reimbursement?
ProMarker Endo: How will it disrupt the market?
Sales strategy without direct sales force
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Proteomics International Laboratories earnings date
H1 202623 Feb, 2026
Next Proteomics International Laboratories earnings date
H1 202623 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Proteomics International Laboratories Ltd is an Australian life sciences company specializing in predictive diagnostics and analytical services based on proteomics, the study of proteins. The company develops diagnostic tests for chronic diseases, with a focus on its flagship product, PromarkerD, a predictive test for diabetic kidney disease. In addition to diagnostics, Proteomics International provides contract research services, including protein analysis, biomarker discovery, and pharmaceutical testing, supporting drug development and medical research. Proteomics International Laboratories Ltd is headquartered in Perth, Australia, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage